Published in J Chromatogr A on May 17, 2010
The cyanobacteria derived toxin Beta-N-methylamino-L-alanine and amyotrophic lateral sclerosis. Toxins (Basel) (2010) 0.98
Presence of the neurotoxin BMAA in aquatic ecosystems: what do we really know? Toxins (Basel) (2014) 0.87
Sample preparation methodology for mouse heart metabolomics using comprehensive two-dimensional gas chromatography coupled with time-of-flight mass spectrometry. Talanta (2013) 0.80
Searching for a link between the L-BMAA neurotoxin and amyotrophic lateral sclerosis: a study protocol of the French BMAALS programme. BMJ Open (2014) 0.78
Rethinking cycad metabolite research. Commun Integr Biol (2011) 0.75
β-methylamino-L-alanine (BMAA) is not found in the brains of patients with confirmed Alzheimer's disease. Sci Rep (2016) 0.75
Cycad neurotoxins, consumption of flying foxes, and ALS-PDC disease in Guam. Neurology (2002) 2.99
Diverse taxa of cyanobacteria produce beta-N-methylamino-L-alanine, a neurotoxic amino acid. Proc Natl Acad Sci U S A (2005) 1.92
Selective vulnerability of preterm white matter to oxidative damage defined by F2-isoprostanes. Ann Neurol (2005) 1.77
Cyanobacterial neurotoxin BMAA in ALS and Alzheimer's disease. Acta Neurol Scand (2009) 1.75
A mechanism for slow release of biomagnified cyanobacterial neurotoxins and neurodegenerative disease in Guam. Proc Natl Acad Sci U S A (2004) 1.67
Clinical features and changing patterns of neurodegenerative disorders on Guam, 1997-2000. Neurology (2002) 1.55
2-Amino-3-(methylamino)-propanoic acid (BMAA) in cycad flour: an unlikely cause of amyotrophic lateral sclerosis and parkinsonism-dementia of Guam. Neurology (1990) 1.40
Chronic exposure to dietary sterol glucosides is neurotoxic to motor neurons and induces an ALS-PDC phenotype. Neuromolecular Med (2008) 1.17
Isolation of various forms of sterol beta-D-glucoside from the seed of Cycas circinalis: neurotoxicity and implications for ALS-parkinsonism dementia complex. J Neurochem (2002) 1.13
Characterisation of lavender essential oils by using gas chromatography-mass spectrometry with correlation of linear retention indices and comparison with comprehensive two-dimensional gas chromatography. J Chromatogr A (2002) 1.10
Animal models of BMAA neurotoxicity: a critical review. Life Sci (2007) 1.06
Identification and evaluation of cycling yeast metabolites in two-dimensional comprehensive gas chromatography-time-of-flight-mass spectrometry data. J Chromatogr A (2007) 1.05
Cyanobacteria and BMAA exposure from desert dust: a possible link to sporadic ALS among Gulf War veterans. Amyotroph Lateral Scler (2009) 1.04
ALS and PDC of Guam: forty-year follow-up. Neurology (2002) 1.03
Determination of the neurotoxin BMAA (beta-N-methylamino-L-alanine) in cycad seed and cyanobacteria by LC-MS/MS (liquid chromatography tandem mass spectrometry). Analyst (2008) 1.02
Parallel factor analysis (PARAFAC) of target analytes in GC x GC-TOFMS data: automated selection of a model with an appropriate number of factors. Anal Chem (2007) 1.01
Comprehensive analysis of yeast metabolite GC x GC-TOFMS data: combining discovery-mode and deconvolution chemometric software. Analyst (2007) 1.00
Time-dependent profiling of metabolites from Snf1 mutant and wild type yeast cells. Anal Chem (2008) 0.94
Parkinson-dementia complex and development of a new stable isotope dilution assay for BMAA detection in tissue. Toxicol Appl Pharmacol (2009) 0.93
Lack of behavioral and neuropathological effects of dietary beta-methylamino-L-alanine (BMAA) in mice. Pharmacol Biochem Behav (2006) 0.93
Genome-wide analysis of the parkinsonism-dementia complex of Guam. Arch Neurol (2004) 0.88
Trends in chemometric analysis of comprehensive two-dimensional separations. Anal Bioanal Chem (2004) 0.88
Role of the cycad neurotoxin BMAA in the amyotrophic lateral sclerosis-parkinsonism dementia complex of the western Pacific. Adv Neurol (1991) 0.87
Automated resolution of nontarget analyte signals in GC x GC-TOFMS data using parallel factor analysis. Anal Chem (2008) 0.86
Simple, non-moving modulation interface for comprehensive two-dimensional gas chromatography. J Chromatogr A (2001) 0.85
Comprehensive two-dimensional gas chromatography via differential flow modulation Anal Chem (2000) 0.82
Comprehensive two-dimensional gas chromatography with time-of-flight mass spectrometric detection applied to the determination of pesticides in food extracts. J Chromatogr A (2002) 0.81
Comprehensive two-dimensional gas chromatography with time-of-flight mass spectrometric detection for the trace analysis of flavour compounds in food. J Chromatogr A (2003) 0.80
Beta-methylamino-L-alanine analysis by liquid chromatography tandem mass spectrometry with iTRAQ as the derivative. Eur J Mass Spectrom (Chichester, Eng) (2009) 0.77
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol (2008) 5.33
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10
Glucose levels and risk of dementia. N Engl J Med (2013) 4.95
Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol (2011) 4.76
Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol (2007) 4.47
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain (2010) 3.57
Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol (2007) 3.55
Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol (2010) 2.91
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol (2011) 2.84
Cyclic changes in metabolic state during the life of a yeast cell. Proc Natl Acad Sci U S A (2007) 2.65
CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol (2008) 2.34
GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology (2012) 2.19
The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration. Arch Neurol (2010) 2.19
Neuropathologic substrates of Parkinson disease dementia. Ann Neurol (2012) 2.10
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis (2006) 2.00
Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease. J Neurosci (2005) 1.89
Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement (2011) 1.87
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87
Faster plasma vitamin E disappearance in smokers is normalized by vitamin C supplementation. Free Radic Biol Med (2005) 1.85
Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. J Alzheimers Dis (2006) 1.82
Ecology of the aging human brain. Arch Neurol (2011) 1.78
Selective vulnerability of preterm white matter to oxidative damage defined by F2-isoprostanes. Ann Neurol (2005) 1.77
Blood pressure and brain injury in older adults: findings from a community-based autopsy study. J Am Geriatr Soc (2009) 1.76
Different patterns of cerebral injury in dementia with or without diabetes. Arch Neurol (2009) 1.76
LR11/SorLA expression is reduced in sporadic Alzheimer disease but not in familial Alzheimer disease. J Neuropathol Exp Neurol (2006) 1.72
Free radical damage to cerebral cortex in Alzheimer's disease, microvascular brain injury, and smoking. Ann Neurol (2009) 1.71
Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem Phys Lipids (2004) 1.63
Surgical neuropathology update: a review of changes introduced by the WHO classification of tumours of the central nervous system, 4th edition. Arch Pathol Lab Med (2008) 1.61
The genetics and neuropathology of Alzheimer's disease. Acta Neuropathol (2012) 1.56
High-speed peak matching algorithm for retention time alignment of gas chromatographic data for chemometric analysis. J Chromatogr A (2003) 1.56
A comprehensive two-dimensional retention time alignment algorithm to enhance chemometric analysis of comprehensive two-dimensional separation data. Anal Chem (2005) 1.55
Effect of apolipoprotein E genotype and diet on apolipoprotein E lipidation and amyloid peptides: randomized clinical trial. JAMA Neurol (2013) 1.52
Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient. Brain Pathol (2008) 1.52
Lewy body pathology in familial Alzheimer disease: evidence for disease- and mutation-specific pathologic phenotype. Arch Neurol (2006) 1.42
Microglial EP2 is critical to neurotoxicity from activated cerebral innate immunity. Glia (2005) 1.42
APOE ε4 increases risk for dementia in pure synucleinopathies. JAMA Neurol (2013) 1.41
Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J Alzheimers Dis (2005) 1.39
Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid. Neurobiol Aging (2005) 1.39
The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis. Ann Neurol (2008) 1.38
Microglia lacking E Prostanoid Receptor subtype 2 have enhanced Abeta phagocytosis yet lack Abeta-activated neurotoxicity. Am J Pathol (2005) 1.38
Inflammatory prostaglandin E2 signaling in a mouse model of Alzheimer disease. Ann Neurol (2012) 1.37
Cardiac-specific deletion of acetyl CoA carboxylase 2 prevents metabolic remodeling during pressure-overload hypertrophy. Circ Res (2012) 1.35
Associations between microinfarcts and other macroscopic vascular findings on neuropathologic examination in 2 databases. Alzheimer Dis Assoc Disord (2009) 1.34
Proteomic analysis of neurofibrillary tangles in Alzheimer disease identifies GAPDH as a detergent-insoluble paired helical filament tau binding protein. FASEB J (2005) 1.33
Hyperinsulinemia provokes synchronous increases in central inflammation and beta-amyloid in normal adults. Arch Neurol (2005) 1.33
Cerebrospinal fluid concentration of brain-derived neurotrophic factor and cognitive function in non-demented subjects. PLoS One (2009) 1.32
Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol (2012) 1.32
A combined dataset of human cerebrospinal fluid proteins identified by multi-dimensional chromatography and tandem mass spectrometry. Proteomics (2007) 1.31
Pharmacologic suppression of neuronal oxidative damage and dendritic degeneration following direct activation of glial innate immunity in mouse cerebrum. J Neurochem (2003) 1.30
Prostaglandin E2 receptor subtype 2 (EP2) regulates microglial activation and associated neurotoxicity induced by aggregated alpha-synuclein. J Neuroinflammation (2007) 1.30
Suppression of murine cerebral F2-isoprostanes and F4-neuroprostanes from excitotoxicity and innate immune response in vivo by alpha- or gamma-tocopherol. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 1.28
Chronic dietary alpha-lipoic acid reduces deficits in hippocampal memory of aged Tg2576 mice. Neurobiol Aging (2006) 1.28
Analysis of alpha-synuclein-associated proteins by quantitative proteomics. J Biol Chem (2004) 1.27
The prostaglandin E2 E-prostanoid 4 receptor exerts anti-inflammatory effects in brain innate immunity. J Immunol (2010) 1.26
Electrophilic cyclopentenone neuroprostanes are anti-inflammatory mediators formed from the peroxidation of the omega-3 polyunsaturated fatty acid docosahexaenoic acid. J Biol Chem (2008) 1.26
A patient with Huntington's disease and long-surviving fetal neural transplants that developed mass lesions. Acta Neuropathol (2008) 1.25
Comprehensive two-dimensional gas chromatography time-of-flight mass spectrometry analysis of metabolites in fermenting and respiring yeast cells. Anal Chem (2006) 1.25
Biomarkers for cognitive impairment and dementia in elderly people. Lancet Neurol (2008) 1.25
Depletion of B lymphocytes from cerebral perivascular spaces by rituximab. Arch Neurol (2009) 1.24
Neurotoxicity from innate immune response is greatest with targeted replacement of E4 allele of apolipoprotein E gene and is mediated by microglial p38MAPK. FASEB J (2006) 1.24
Biomarkers of oxidative damage and inflammation in Alzheimer's disease. Biomark Med (2010) 1.24
U1 small nuclear ribonucleoprotein complex and RNA splicing alterations in Alzheimer's disease. Proc Natl Acad Sci U S A (2013) 1.23
Male microchimerism in the human female brain. PLoS One (2012) 1.21
Prostaglandin H(2)-derived adducts of proteins correlate with Alzheimer's disease severity. J Neurochem (2005) 1.21
Diabetes and insulin in regulation of brain cholesterol metabolism. Cell Metab (2010) 1.19
Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models. Free Radic Biol Med (2008) 1.19
Proteomic identification of novel proteins in cortical lewy bodies. Brain Pathol (2007) 1.19
PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. Acta Neuropathol (2015) 1.17
Neuronal oxidative damage and dendritic degeneration following activation of CD14-dependent innate immune response in vivo. J Neuroinflammation (2004) 1.15
Diet intervention and cerebrospinal fluid biomarkers in amnestic mild cognitive impairment. Arch Neurol (2011) 1.15
HIV associated neurodegeneration requires p53 in neurons and microglia. FASEB J (2004) 1.15
Apolipoprotein E isoforms and apolipoprotein AI protect from amyloid precursor protein carboxy terminal fragment-associated cytotoxicity. J Neurochem (2004) 1.14
Apolipoprotein E-specific innate immune response in astrocytes from targeted replacement mice. J Neuroinflammation (2006) 1.14
Plasma apolipoprotein A1 as a biomarker for Parkinson disease. Ann Neurol (2013) 1.14
Therapeutic targets in prostaglandin E2 signaling for neurologic disease. Curr Med Chem (2008) 1.14
Familial prion disease with Alzheimer disease-like tau pathology and clinical phenotype. Ann Neurol (2011) 1.13
Manganese ethylene-bis-dithiocarbamate and selective dopaminergic neurodegeneration in rat: a link through mitochondrial dysfunction. J Neurochem (2003) 1.13
Pacific Northwest Udall Center of excellence clinical consortium: study design and baseline cohort characteristics. J Parkinsons Dis (2013) 1.12
PGH2-derived levuglandin adducts increase the neurotoxicity of amyloid beta1-42. J Neurochem (2006) 1.12
Effects of reactive gamma-ketoaldehydes formed by the isoprostane pathway (isoketals) and cyclooxygenase pathway (levuglandins) on proteasome function. FASEB J (2002) 1.11
Combined deficiency of vitamins E and C causes paralysis and death in guinea pigs. Am J Clin Nutr (2003) 1.09
Suppressed accumulation of cerebral amyloid {beta} peptides in aged transgenic Alzheimer's disease mice by transplantation with wild-type or prostaglandin E2 receptor subtype 2-null bone marrow. Am J Pathol (2010) 1.09
White matter lesions defined by diffusion tensor imaging in older adults. Ann Neurol (2011) 1.09
Algorithm for locating analytes of interest based on mass spectral similarity in GC x GC-TOF-MS data: analysis of metabolites in human infant urine. J Chromatogr A (2004) 1.08
ABCC9 gene polymorphism is associated with hippocampal sclerosis of aging pathology. Acta Neuropathol (2014) 1.07
Suppression of longitudinal increase in CSF F2-isoprostanes in Alzheimer's disease. J Alzheimers Dis (2004) 1.07
Proteomic determination of widespread detergent-insolubility including Abeta but not tau early in the pathogenesis of Alzheimer's disease. FASEB J (2005) 1.06
{alpha}-Tocopherol disappearance is faster in cigarette smokers and is inversely related to their ascorbic acid status. Am J Clin Nutr (2005) 1.06
Digestion products of the PH20 hyaluronidase inhibit remyelination. Ann Neurol (2013) 1.06
Prostaglandin H2 (PGH2) accelerates formation of amyloid beta1-42 oligomers. J Neurochem (2002) 1.05
Identification and evaluation of cycling yeast metabolites in two-dimensional comprehensive gas chromatography-time-of-flight-mass spectrometry data. J Chromatogr A (2007) 1.05